Share capital and voting rights in Orphazyme A/S
Mar 29, 2019
Following a share capital increase in Orphazyme A/S (ticker: ORPHA.CO), CVR no. 32266355 (“Orphazyme”) in March 2019, the total nominal share capital of Orphazyme is DKK 19,984,799, divided into 19,984,799 shares each with a nominal value of DKK 1. Each share carries one vote at Orphazyme’s general meetings and accordingly the total number of voting rights in Orphazyme is 19,984,799.
Share capital and voting rights in Orphazyme as
Read moreResolution passed at the Annual General Meeting
Mar 27, 2019
Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today held its Annual General Meeting, at which the Annual General Meeting.
Resolutions passed at the annual general meeting
Read moreOrphazyme to present at Cowen & Co Annual Health Care Conference
Mar 11, 2019
Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that Anders Hinsby, Chief Executive Officer at Orphazyme, will be presenting at the Cowen & Co Annual Health Care Conference in Boston, MA, USA on March 12, 2019.
Orphazyme to present at cowen co annual health care
Read moreReporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Mar 8, 2019
Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme.
Reporting of transactions in Orphazymes shares
Read moreReporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Mar 7, 2019
Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme.
Reporting of transactions in Orphazymes shares
Read moreNotice to convene Annual General Meeting
Mar 5, 2019
Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that the Orphazyme A/S Annual General Meeting will be held on ...
Notice to convene annual general meeting
Read moreReporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Mar 4, 2019
Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme in connection with the vesting of Matching Shares.
Reporting of transactions in Orphazymes shares
Read moreOrphazyme announces Annual Report 2018
Mar 1, 2019
Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced its Annual Report for 2018. Below is a summary from the report of Orphazyme’s business progress, financial performance for the year, and guidance for 2019. The full report is attached as a PDF file and can furthermore be found on the Company's website www.orphazyme.com.
Orphazyme announces annual report 2018
Read moreOrphazyme Annual Report 2018 Presentation
Feb 25, 2019
Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that the Company will be hosting an investor call at which Chief Executive Officer, Anders Hinsby, and Chief Financial Officer, Anders Vadsholt, will be presenting the Orphazyme Annual Report 2018. The presentation will be followed by a Q&A session.
Orphazyme annual report 2018 presentation
Read moreCapital increase of 26,060 shares (equivalent to approximately 0.13% of the existing shares) in Orphazyme A/S as a result of an issue of bonus shares to KLSDC and UCLB
Jan 31, 2019
Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today decided on a capital increase as a result of a directed issue of bonus shares to Kansas Life Sciences Development Company, Inc. (“KLSDC”) and UCL Business PLC (“UCLB”). The capital increase was decided pursuant to the Board of Directors’ authorization laid down in Article 3.6 of the Articles of Association.
Capital increase of 26 060 shares ...
Read more